Womenra: Restore Female Sexual Desire and Satisfaction
Womenra
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | 5.85 $ | 58.50 $ (0%) | 🛒 Add to cart |
| 20 | 3.51 $ | 117.00 $ 70.20 $ (40%) | 🛒 Add to cart |
| 30 | 2.73 $ | 175.50 $ 81.90 $ (53%) | 🛒 Add to cart |
| 60 | 1.75 $ | 351.00 $ 105.30 $ (70%) | 🛒 Add to cart |
| 90 | 1.43 $ | 526.50 $ 128.70 $ (76%) | 🛒 Add to cart |
| 120 | 1.36 $ | 702.00 $ 163.80 $ (77%) | 🛒 Add to cart |
| 180 | 1.17 $ | 1053.00 $ 210.60 $ (80%) | 🛒 Add to cart |
| 270 | 1.04 $ | 1579.50 $ 280.80 $ (82%) | 🛒 Add to cart |
| 360 | 0.97 $
Best per pill | 2106.00 $ 351.00 $ (83%) | 🛒 Add to cart |
Womenra is a clinically developed prescription medication designed to address the complex challenge of hypoactive sexual desire disorder (HSDD) in premenopausal women. As the first and only non-hormonal, on-demand treatment of its kind, it offers a targeted approach to enhancing sexual motivation and response. By focusing on neurotransmitter activity in key brain regions, Womenra helps reignite natural desire, reduce distress associated with low libido, and improve overall sexual experiences, providing a scientifically-backed solution for a condition that significantly impacts quality of life and intimate relationships.
Features
- Active ingredient: Bremelanotide
- Administration: Subcutaneous autoinjector pen
- On-demand dosing: Taken approximately 45 minutes before anticipated sexual activity
- Non-hormonal mechanism of action
- Prescription-only medication
- Single-use pre-filled dosage system
Benefits
- Increases spontaneous sexual desire and responsive arousal
- Reduces personal distress associated with low sexual desire
- Enhances satisfaction with sexual experiences and emotional connection
- Improves overall sexual function as measured by validated assessment tools
- Provides predictable, on-demand efficacy without daily dosing commitment
- Offers a non-hormonal alternative to existing treatments
Common use
Womenra is specifically indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by another medical condition, substance use, or severe relationship distress. The condition must be acquired (developing in a patient who previously had no problems with sexual desire) and generalized (not situational or partner-specific).
Dosage and direction
The recommended dosage is 1.75 mg administered subcutaneously in the abdomen or thigh using the provided autoinjector pen. Administration should occur approximately 45 minutes before anticipated sexual activity. Patients may use Womenra as needed, but not more than once within 24 hours and no more than 8 times per month. Proper injection technique should be demonstrated by a healthcare provider, including site rotation and safe disposal of used pens. The medication should be inspected visually for particulate matter and discoloration before administration.
Precautions
Patients should be counseled that Womenra may cause transient increases in blood pressure and decreases in heart rate that typically resolve within 12 hours. Blood pressure should be monitored periodically. The medication may cause nausea; taking it with food may reduce this effect. Womenra may cause darkening of the skin and gums; this effect is reversible upon discontinuation but may persist for several months. Patients should avoid concomitant use with alcohol. The autoinjector contains a needle; proper disposal in a sharps container is essential to prevent needlestick injuries.
Contraindications
Womenra is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. It should not be used by patients taking concomitant naltrexone or other opioid antagonists due to potential interference with mechanism of action. Contraindicated in patients with a history of hypersensitivity to bremelanotide or any component of the formulation. Not recommended for use in postmenopausal women or men. Should not be used by patients with hepatic or severe renal impairment.
Possible side effects
The most common adverse reactions (incidence ≥4% and greater than placebo) include nausea (40%), flushing (20%), injection site reactions (13%), headache (11%), vomiting (8%), and nasopharyngitis (5%). Less common side effects include fatigue, dizziness, and skin hyperpigmentation. Most side effects are mild to moderate in severity and tend to decrease in frequency with continued use. Serious side effects are rare but may include severe hypertension or significant changes in heart rate.
Drug interaction
Womenra may have interactions with medications that affect blood pressure, including antihypertensives and vasodilators. Concurrent use with naltrexone or other opioid antagonists is contraindicated. Caution is advised with medications that affect serotonin levels, though no specific serotonin-related interactions have been identified. The effect of alcohol may be potentiated, and concurrent use should be avoided. No significant interactions with hormonal contraceptives have been observed.
Missed dose
As Womenra is taken on an as-needed basis approximately 45 minutes before sexual activity, there is no scheduled dosing to miss. If a dose is prepared but not administered, the medication should be properly discarded. If sexual activity does not occur after administration, no additional dose should be taken within 24 hours. Patients should not attempt to “make up” a missed dose.
Overdose
There is limited experience with overdose. Single doses up to 4.5 mg (approximately 2.5 times the recommended dose) have been administered in clinical trials, resulting in increased incidence and severity of adverse effects including nausea, vomiting, and flushing. In case of suspected overdose, symptomatic and supportive care is recommended, with particular attention to blood pressure monitoring and management. There is no specific antidote for bremelanotide overdose.
Storage
Store Womenra in the original packaging in a refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light. If needed, the autoinjector may be kept at room temperature (up to 25°C/77°F) for up to 30 days in the original carton. Once removed from refrigeration and brought to room temperature, the product must be used within 30 days or discarded. Do not return to refrigeration after reaching room temperature. Keep out of reach of children and pets.
Disclaimer
Womenra is available by prescription only and should be used under the supervision of a qualified healthcare provider. This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Individual results may vary. Patients should discuss their medical history and any current medications with their healthcare provider before starting treatment. Only a healthcare provider can determine if Womenra is appropriate for a particular patient based on their individual health status and needs.
Reviews
Clinical trial data demonstrate that 25-35% of women treated with Womenra achieved meaningful improvement in sexual desire scores compared to 17-20% with placebo. Patient-reported outcomes showed significant improvements in distress related to sexual desire and overall sexual satisfaction. Real-world evidence continues to accumulate showing sustained benefits with appropriate use. Many patients report restoration of sexual intimacy and improvement in relationship quality. Healthcare providers note the importance of proper patient selection and education for optimal outcomes.